Corient Private Wealth LLC Has $347,000 Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Corient Private Wealth LLC lessened its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 4.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 8,827 shares of the company’s stock after selling 365 shares during the period. Corient Private Wealth LLC’s holdings in CRISPR Therapeutics were worth $347,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Highline Wealth Partners LLC bought a new position in CRISPR Therapeutics in the fourth quarter valued at approximately $39,000. Western Pacific Wealth Management LP raised its stake in shares of CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after purchasing an additional 500 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of CRISPR Therapeutics in the 3rd quarter valued at approximately $40,000. Spire Wealth Management grew its stake in shares of CRISPR Therapeutics by 303.7% in the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock valued at $78,000 after buying an additional 1,482 shares in the last quarter. Finally, MCF Advisors LLC acquired a new position in CRISPR Therapeutics during the fourth quarter worth $80,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock opened at $36.99 on Monday. CRISPR Therapeutics AG has a 52-week low of $36.52 and a 52-week high of $68.39. The stock has a market cap of $3.17 billion, a PE ratio of -8.46 and a beta of 1.77. The firm has a 50-day moving average of $43.10 and a 200-day moving average of $45.17.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Equities research analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Citigroup cut their price target on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a research note on Tuesday, February 18th. JMP Securities reiterated a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Truist Financial lifted their price target on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, February 12th. Needham & Company LLC restated a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, February 12th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $73.11.

Insider Buying and Selling

In other news, CEO Samarth Kulkarni sold 18,360 shares of the firm’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the sale, the chief executive officer now directly owns 171,613 shares in the company, valued at approximately $9,473,037.60. This trade represents a 9.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Julianne Bruno sold 1,198 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $50,819.16. Following the completion of the transaction, the chief operating officer now owns 8,263 shares of the company’s stock, valued at $350,516.46. The trade was a 12.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 32,381 shares of company stock valued at $1,608,243 over the last quarter. 4.10% of the stock is owned by company insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.